Contact
searchSearch
HMP Global
Login

LEUKEMIA & LYMPHOMA

Test Your Knowledge
Quiz: What is the Most Common Type of Lymphoma?
11/17/2021
There are a number of different types of lymphomas. Which is the most common?
There are a number of different types of lymphomas. Which is the most common?
There are a number of different...
11/17/2021
Oncology
Videos
Should You Stop TKI Treatment for CML in Major Molecular Response?
12/23/2019
Sangmin Lee, MD, discusses whether or not you should stop TKI treatment in patients with CML in major molecular response.
Sangmin Lee, MD, discusses whether or not you should stop TKI treatment in patients with CML in major molecular response.
Sangmin Lee, MD, discusses...
12/23/2019
Oncology
Comparing Sequential Monotherapy With Combo Therapy in CLL
10/25/2019
John Allan, MD, shares important considerations for comparing sequential monotherapy with combination therapy in CLL.
John Allan, MD, shares important considerations for comparing sequential monotherapy with combination therapy in CLL.
John Allan, MD, shares important...
10/25/2019
Oncology
Comparing Sequential Monotherapy With Combo Therapy in CLL
10/25/2019
John Allan, MD, shares important considerations for comparing sequential monotherapy with combination therapy in CLL.
John Allan, MD, shares important considerations for comparing sequential monotherapy with combination therapy in CLL.
John Allan, MD, shares important...
10/25/2019
Oncology
News
Management of Patients With Relapsed T-Cell ALL
10/23/2019
Pinkal Desai, MD, MPH, discusses the management of difficult cases of ALL, particularly relapsed T-cell disease.
Pinkal Desai, MD, MPH, discusses the management of difficult cases of ALL, particularly relapsed T-cell disease.
Pinkal Desai, MD, MPH, discusses...
10/23/2019
Oncology
Selecting, Switching, and Discontinuing First-Line TKIs in CML
10/23/2019
Dr Lee tells attendees of the Lymphoma & Myeloma Congress about current approaches to optimizing the care of patients with CML in the era of TKIs.
Dr Lee tells attendees of the Lymphoma & Myeloma Congress about current approaches to optimizing the care of patients with CML in the era of TKIs.
Dr Lee tells attendees of the...
10/23/2019
Oncology
Videos
Richard Furman, MD, Discusses Richter's Transformation and Emerging Therapies in CLL
11/08/2018
Dr Furman discusses disease progression with BTK inhibitor therapy, Richter's transformation, and emerging treatment options for CLL.
Dr Furman discusses disease progression with BTK inhibitor therapy, Richter's transformation, and emerging treatment options for CLL.
Dr Furman discusses disease...
11/08/2018
Oncology
Videos
Jonathon Cohen, MD, Discusses Treatment Options and Prognosis in MCL
11/08/2018
Dr Cohen discusses the available treatment options for patients with MCL, and describes methods for predicting patient response to specific therapies.
Dr Cohen discusses the available treatment options for patients with MCL, and describes methods for predicting patient response to specific therapies.
Dr Cohen discusses the available...
11/08/2018
Oncology
Therapies are Rapidly Evolving for Patients With Newly Diagnosed AML
10/17/2018
At the 2018 L&M congress, Gail Roboz, MD, discussed current therapy options for patients with newly diagnosed AML.
At the 2018 L&M congress, Gail Roboz, MD, discussed current therapy options for patients with newly diagnosed AML.
At the 2018 L&M congress, Gail...
10/17/2018
Oncology
MRD Testing a Crucial Component in Treatment of Patients With AML
10/17/2018
Clinicians should measure MRD in their patients with AML, because CR on its own is simply not enough, Gail J. Roboz, MD, asserted at the 2018 L&M congress.
Clinicians should measure MRD in their patients with AML, because CR on its own is simply not enough, Gail J. Roboz, MD, asserted at the 2018 L&M congress.
Clinicians should measure MRD in...
10/17/2018
Oncology

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use